




RealRate

PHARMACEUTICAL 2021

Benitec Biopharma Inc
Rank 144 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Benitec Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Benitec Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Benitec Biopharma Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 313%, being 57% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	10,809
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,136
Liabilities, Non-Current	213
Other Assets	404
Other Compr. Net Income	-89
Other Expenses	-185
Other Liabilities	0
Other Net Income	7.0
Other Revenues	102
Property and Equipment	374
Research and Development	3,001
Selling, General and Administrative Expense	5,567

Output Variable	Value in 1000 USD
Assets	11,587
Liabilities	1,349
Expenses	8,383
Revenues	102
Stockholders Equity	10,238
Net Income	-8,274
Comprehensive Net Income	-8,318
BaseVar	10,758
ECR before Limited Liability	216%
Economic Capital Ratio	313%